Publications by authors named "Dee Silver"

Claim this Profile
O
Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.
Alberto J Espay, Fernando L Pagan, Benjamin L Walter, John C Morgan, Lawrence W Elmer, Dee E Silver

Neurol Clin Pract· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson disease.
Dee E Silver, Richard M Trosch

Neurology· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
Cheryl H Waters, Paul Nausieda, Lyudmila Dzyak, Joerg Spiegel, Monika Rudzinska, Dee E Silver

CNS Drugs· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.
Robert A Hauser, Dee Silver, Azhar Choudhry, Eli Eyal, Stuart Isaacson

Mov Disord· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.
Ronald E Wilson, Lauren C Seeberger, Dee Silver, Alida Griffith, Jill B Conner

Neurologist· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review.
Dee E Silver, Philip O Buck

Int J Neurosci· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease.
William G Ondo, Christine Hunter, Stuart H Isaacson, Dee E Silver, R Malcolm Stewart

Parkinsonism Relat Disord· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
Kelly E Lyons, Joseph H Friedman, Neal Hermanowicz, Stuart H Isaacson, Robert A Hauser, Dee E Silver

Clin Neuropharmacol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis.
William L Baker, Dee Silver, C Michael White, Jeffrey Kluger, Jeffrey Aberle

Parkinsonism Relat Disord· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacologic management of Parkinson's disease in long-term care residents: maintaining functionality to improve quality of life.
Dee E Silver

Director· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease: a 6-month open-label study.
Richard M Trosch, Dee Silver, Peter B Bottini

CNS Drugs· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early, nondisabling Parkinson's disease: weighing the options for initial therapy.
Dee E Silver

Neurol Clin· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
Mark Stacy, Dee Silver

Parkinsonism Relat Disord· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of functional age on the use of dopamine agonists in patients with Parkinson disease.
Dee Silver

Neurologist· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
Dee E Silver

Expert Rev Neurother· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis